华西证券（002926）发布研报称，维持江南布衣(03306)"买入"评级，FY26-28公司收入预测 60.04/63.96/68.06亿元，同比增长8.21%/6.53%/6.41%，归母净利润预测9.71/10.40/11.15亿元，同比增长 8.72%/7.08%/7.24%，对应FY26-28年EPS预测为1./1.9286/2.09元，26年2月26日公司收盘价20.08港元对 应PE为9.4/9.1/8.3X。 华西证券主要观点如下： 事件概述 未来展望 短期来看，公司年初以来流水持续较快增长，公司的成长品牌及新兴品牌仍有较大开店空间，未来随着 大店占比提升、多品牌集合店增加、低效直营店转加盟、粉丝经济带动离店销售等，店效仍有较大提升 空间;中长期来看，粉丝粘性有望带动公司毛利率稳中有升、规模效应带动费用下降，有望带动公司净 利率进一步增长。 (2)分渠道来看，FY2026H1直营/经销/线上收入分别为11.80/14.42/7.53亿元，同比增长 5.7%/0.3%/25.1%，直营/经销门店数分别为512/1651家，同比增长4%/1%，FY2026H1直营店效/经销单 店出货分别为230/ ...

毛利率及归母净利率上升1.4/0.9PCT，归母净利率增速低于毛利率主要由于管理费用率和所得税费用率 提升、财务收入下降。FY2026H1毛利率为66.5%、同比提升1.4PCT(1)分品牌毛利率来看，主品牌毛利 率稳健：JNBY/速写/jnby by JNBY/LESS/新兴品牌毛利率分别为69.4%/67.5%/60.2%/70.5%/48.8%、同比 提升1.8/2.0/1.8/1.7/-3.6PCT。(2)分渠道毛利率来看，直营/经销/线上毛利率分别为73.7%/61.0%/65.8%， 同比提升0.1/2.0/1.6PCT;(3)2026H1归母净利率为20.0%、同比上升0.9PCT。从费用率看，FY2026H1销 售/管理/财务费用率分别为32.4%/9.2%/0.17%、同比增加0.1/0.6/-0.17PCT，管理费用提升主要由于产品 设计和研发部门开支增加。其他收益/收入占比提升0.47PCT，主要由于创业投资基金的公允价值变动收 益增加，所得税/收入同比提升0.2PCT。 存货有所增长 智通财经APP获悉，华西证券发布研报称，维持江南布衣(03306)"买入"评级，FY26-28公司收入 ...

华西证券（002926）发布研报称，春节作为餐饮消费的核心旺季，2026年节庆效应持续凸显，餐饮消费 回暖态势明确，为上游供应链复苏奠定坚实基础。细分赛道来看，速冻食品与调味品充分受益于旺季需 求拉动。随着餐饮门店客流回升与开店节奏加快，餐饮占比较高的头部企业有望率先承接需求红利，实 现销量与收入的稳步增长。该行维持"服务消费率先复苏"的核心判断，板块业绩与估值共振上行。 商务部数据显示，春节假期全国重点零售和餐饮企业日均销售额同比增长5.7%，78个重点步行街(商圈) 客流量同比提升6.7%、营业额同比增长7.5%，双重数据印证餐饮消费复苏势头强劲，终端需求韧性超 预期。 投资建议 从终端场景拆分来看，节日聚餐需求爆发式增长，美团年夜饭预订订单同比增长105%，抖音年夜饭团 购销售额同比增长185%，彰显C端消费活力;同时，春节出行链持续高景气，带动目的地餐饮需求同步 升温，景区、核心商圈餐饮客流大幅攀升，B端餐饮场景复苏节奏加快。区域数据方面，江苏省春节9 天假期餐饮收入达183亿元，同比增长11.9%，成为区域餐饮消费复苏的标杆，侧面反映全国范围内餐 饮消费的全面回暖态势。 旺季需求传导至上游，备货和动 ...

华西证券研报表示，近期中国AI大模型迎来"春节档"爆发，技术趋势已从通用聊天工具全面转向垂直生 产力工具与真实Agent落地，重点体现在工业级的视频生成（如Seedance 2.0的多模态叙事与音画同 步）、工程级编程（如智谱GLM-5的跨文件重构与系统工程能力）以及消费办公场景。当前时点，面 临近期的流动性担忧以及海外OpenAI资本开支预期的变化，反映市场对于当前AI发展逐渐聚焦于成本 效益比率，预计市场仍将保持震荡，板块建议相对谨慎，中性配置。目前AI发展阶段仍处于Scale up和 Scale out的关键加速期，伴随相关算力芯片的供应体系逐渐丰富，应用发展对于token需求量仍在加速增 加，相关底层算力基建仍然还在扩张期。仍坚定看好Scale up的柜内光升级，电源、液冷等产业领域向 国产厂商升级机遇，国产算力包括芯片、交换机、服务器等需求放量，以及CSP厂商资本开支加速带来 的算力租赁和AIDC相关市场机遇。 ...

（文章来源：第一财经） 华西证券研报表示，近期中国AI大模型迎来"春节档"爆发，技术趋势已从通用聊天工具全面转向垂直生 产力工具与真实Agent落地，重点体现在工业级的视频生成（如Seedance 2.0的多模态叙事与音画同 步）、工程级编程（如智谱GLM-5的跨文件重构与系统工程能力）以及消费办公场景。当前时点，面 临近期的流动性担忧以及海外OpenAI资本开支预期的变化，反映市场对于当前AI发展逐渐聚焦于成本 效益比率，预计市场仍将保持震荡，板块建议相对谨慎，中性配置。目前AI发展阶段仍处于Scale up和 Scale out的关键加速期，伴随相关算力芯片的供应体系逐渐丰富，应用发展对于token需求量仍在加速增 加，相关底层算力基建仍然还在扩张期。仍坚定看好Scale up的柜内光升级，电源、液冷等产业领域向 国产厂商升级机遇，国产算力包括芯片、交换机、服务器等需求放量，以及CSP厂商资本开支加速带来 的算力租赁和AIDC相关市场机遇。 ...

华西证券研报指出，探路者拟向72名激励对象授予672.68万股限制性股票，占公司股本总额0.76%，授 予价格为7.08元/股。此次股权激励计划为新董事长李总自2021年上任后的首次激励，有望提振市场信 心。近年来，户外行业势头发展迅猛，接替了此前的运动趋势成为下一个服装细分行业增长点。探路者 主业在产品功能性提升、加大营销投入、店效改善上发力，未来期待终端折扣率改善带来品牌力重塑及 盈利能力改善。从芯片业务来看,G2Touch的并购较为成功、主要受益于技术开发及下游客户开拓，未来 有望在车载领域仍存在拓展空间，公司依赖ONCELL技术优势、未来也有望发展INCELL技术，新收购 公司有望形成优势互补，为业绩提供新增量。公司发布了下肢外骨骼、5G智能户外手表、智能滑雪头 盔和悬镜式高清户外影院等四款户外智能装备，在助力效果、续航时间、适应性、轻量化、智能交互等 方面均有改善。维持25年-27年盈利预测，维持25-27年收入预测20.11/28.29/33.42亿元；维持25-27年归 母净利预测2.37/3.69/4.54亿元；对应维持25-27EPS预测0.26/0.42/0.51元。2026年2月13日收 ...

Core Viewpoint - The articles reflect on the achievements of the securities and fund industry in 2025, emphasizing the importance of integrating political and economic goals while looking forward to the opportunities and challenges in 2026 as part of the "15th Five-Year Plan" [1][4]. Group 1: Industry Achievements - The securities industry has seen significant transformation and high-quality development, with a successful completion of the "14th Five-Year Plan" [1]. - The company has actively integrated into national strategies, enhancing its core competitive advantages and service capabilities, resulting in impressive performance [1]. - The focus has been on supporting the real economy, particularly small and medium enterprises, and contributing to regional economic development [2]. Group 2: Innovation and Development - The company has emphasized innovation and differentiation, establishing a development pattern centered on regional and industry-specific needs [3]. - A customer-centric service model has been developed, combining chief service officers with product experts to enhance client engagement [3]. - Technological advancements have been prioritized, with initiatives like AI-enabled research and data collaboration platforms being implemented [3]. Group 3: Future Outlook - The year 2026 is seen as a pivotal year for deepening high-quality development in the capital market, with a commitment to serving the real economy and adhering to financial principles [4]. - The company aims to continue its focus on customer service and national strategies, contributing to social welfare and economic prosperity [4]. - There is a call for collaboration and dedication to navigating the challenges and opportunities ahead, with a strong commitment to the financial sector's mission [4].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - In 2025, the number and scale of issued accounts - receivable asset - backed securities increased year - on - year. The actual financiers were still concentrated in construction central enterprises and their subsidiaries, with a more prominent head - effect. These entities were more inclined to introduce in - system factoring companies, capital companies, asset management companies, trust companies, other financial platforms, and off - system commercial factoring companies as original equity holders or agents of original equity holders to issue securitized products. - In 2025, the average issuance scale of single accounts - receivable asset - backed special plans decreased compared to the previous year, the product term was slightly shortened, the issuance interest rate continued to decline, the securities were mainly of AAAsf credit rating, and the overall product credit risk remained at a low level. The trading activity in the secondary market increased significantly [38]. 3. Summary According to the Directory Issuance Situation - In 2025, 157 accounts - receivable asset - backed securitization products were issued in the exchange market, with a total issuance scale of 180.806 billion yuan. The number of issuances increased by 22, and the issuance scale rose by 9.40% year - on - year. The issuance scale accounted for 12.37% of the total issuance scale of enterprise asset - securitization products for the whole year, a decrease of 0.85 percentage points year - on - year [4][5]. - In terms of issuance venues, 140 products with an issuance amount of 172.474 billion yuan (accounting for 95.39%) were issued on the Shanghai Stock Exchange, and 17 products with an issuance amount of 8.332 billion yuan (accounting for 4.61%) were issued on the Shenzhen Stock Exchange [8]. - Regarding the distribution of original equity holders, the top five original equity holders were China Railway Capital Co., Ltd., China Railway Trust Co., Ltd., China Railway Construction Asset Management Co., Ltd., CCCC Commercial Factoring Co., Ltd., and Shenzhen United Factoring Co., Ltd., with issuance scale proportions of 32.27%, 16.95%, 11.06%, 2.73%, and 2.48% respectively. The total issuance scale of the top five original equity holders was 118.429 billion yuan, accounting for 65.50%; the total issuance scale of the top ten was 134.983 billion yuan, accounting for 74.66% [8]. - In terms of actual financiers, the total issuance scale of the top ten actual financiers was 165.964 billion yuan, accounting for 91.79%, an increase of 1.89 percentage points year - on - year. The actual financiers were mainly concentrated in central enterprises and their subsidiaries, with an issuance scale of 162.126 billion yuan, accounting for 89.67%, a year - on - year increase of 3.06 percentage points. In terms of industries, the actual financiers in the construction industry had an issuance scale of 165.423 billion yuan, accounting for 91.49% [10]. - Regarding the distribution of managers, the top five managers with the highest proportion of new management scale were CITIC Securities Co., Ltd., Huaxi Securities Co., Ltd., Ping An Securities Co., Ltd., Shanghai Guotai Haitong Securities Asset Management Co., Ltd., and CITIC Construction Securities Co., Ltd., with scale proportions of 17.61%, 16.95%, 14.64%, 10.13%, and 9.39% respectively. The total new management scale of the top five managers was 124.244 billion yuan, accounting for 68.72%, a year - on - year increase of 5.54 percentage points; the total new management scale of the top ten managers was 160.486 billion yuan, accounting for 88.76%, a year - on - year increase of 9.70 percentage points [14]. - In terms of product scale distribution, the highest single - product issuance scale was 5.4 billion yuan, and the lowest was 100 million yuan. The products with a single - scale in the (5, 10] billion yuan range had the largest number of issuances, with 51 units and a scale proportion of 21.47%. The average single - issuance scale was 1.152 billion yuan, a decrease of 73 million yuan compared to the previous year [16]. - Regarding the term distribution, the shortest term was 0.69 years, and the longest was 4.99 years. The products with a term in the (1, 3] - year range had the largest number of issuances, with 88 units and a scale proportion of 49.97%. The weighted average term was 2.14 years, slightly shorter than the previous year [17]. - In terms of level distribution, in 2025, AAAsf - rated securities accounted for 90.08%, AA + sf - rated securities accounted for 6.33%, and sub - grade securities accounted for 3.59% [19]. - Regarding the issuance interest rate, the median issuance interest rate of AAAsf - rated securities with a term of around 1 year was 1.85%, a year - on - year decrease of about 29BP [4][21]. Issuance Spread Statistical Analysis - Compared with government bonds of the same term, the average issuance spreads of 1 - year and 3 - year accounts - receivable asset - backed securities in 2025 narrowed compared to the previous year. For example, the average 1 - year spread decreased from 0.74 percentage points in 2024 to 0.48 percentage points in 2025 [26][28]. - Compared with AAA - rated corporate bonds of the same term, the average issuance spreads of 1 - year and 3 - year AAAsf - rated accounts - receivable asset - backed securities in 2025 also narrowed compared to the previous year. The average 1 - year spread decreased from 0.18 percentage points in 2024 to 0.14 percentage points in 2025 [31][32]. - In terms of issuance cost, the average issuance interest rate of 1 - year AAAsf - rated accounts - receivable asset - backed securities issued in 2025 decreased by 32BP year - on - year [32]. Filing Situation - In 2025, 105 accounts - receivable asset - backed special plans were filed with the Asset Management Association of China, with a total scale of 129.051 billion yuan. Compared with the previous year, the number of filings decreased by 12, and the filing scale decreased by 14.02% [4][33]. Secondary Market Trading Situation - In 2025, accounts - receivable asset - backed securities had 5,596 transactions in the secondary market, a year - on - year increase of 102.90%. The total transaction scale was 147.768 billion yuan, a year - on - year increase of 47.63%. The transaction scale accounted for 13.76% of the total transaction scale of enterprise asset - backed securities in the current period, a decrease of 1.11 percentage points year - on - year, ranking second in terms of transaction scale [4][36]. Maturity Situation in 2026 - It is estimated that 261 outstanding accounts - receivable asset - backed securities will mature in the exchange market in 2026, with a maturity scale of 168.808 billion yuan, accounting for 21.19% of the total maturity scale of all enterprise asset - backed securities in 2026, ranking second in terms of maturity scale [4][37]. - From the perspective of original equity holders, China Railway Capital Co., Ltd. had 43 maturing accounts - receivable asset - backed securities, with a repayment scale of 43.229 billion yuan, accounting for 25.61%; China Railway Trust Co., Ltd. had 33 maturing securities, with a repayment scale of 33.605 billion yuan, accounting for 19.91%; China Railway Construction Asset Management Co., Ltd. had 22 maturing securities, with a repayment scale of 25.449 billion yuan, accounting for 15.08% [37].

Group 1 - The overall profitability of the company is under temporary pressure due to market channel adjustments and the expansion of low-margin new businesses, leading to a downward revision of revenue and profit forecasts for the years 2025-2027 [1] - The company's revenue forecast for 2025-2027 has been adjusted from 7.83/8.24/8.62 billion to 7.49/7.90/8.26 billion, and the net profit forecast has been revised from 300/360/430 million to 240/270/320 million [1] - The earnings per share (EPS) forecast for 2025-2027 has been lowered from 0.17/0.20/0.24 to 0.13/0.15/0.18, with a current price-to-earnings (P/E) ratio of 14/12/10 times based on the closing price of HKD 1.96 on February 9, 2026 [1] Group 2 - The domestic milk powder market continues to face challenges, while overseas markets are leading growth, with a significant increase in revenue from overseas markets, particularly in the Middle East, North America, and the CIS [2] - The company expects a decline in domestic goat and cow milk powder business in 2025, but anticipates improvement in 2026 as domestic channels become more streamlined [2] - The company remains optimistic about future market developments and plans to continue expanding in the Middle East and other channels like Walmart in the U.S. to create a clear growth blueprint [2] Group 3 - The company has achieved significant recognition in the milk powder sector, with its brand being recognized as the top-selling nutritional milk powder for three consecutive years [3] - The approval of a new strain of probiotics for infant use marks a significant milestone for the company, enhancing its core technological capabilities and supporting the industrialization of "Chinese bacteria" [3] - The company aims to solidify its market position and expand its growth curve through consumer-centric strategies and research innovation, aspiring to become the most trusted formula milk and nutrition health company globally [3]

Group 1 - The overall profitability of Ausnutria (01717) is expected to face temporary pressure due to market channel adjustments and the expansion of low-margin new businesses, leading to a downward revision of revenue and profit forecasts for 2025-2027 [1] - Revenue forecasts for 2025-2027 have been adjusted from 7.83/8.24/8.62 billion to 7.49/7.90/8.26 billion, while net profit forecasts have been revised from 300/360/430 million to 240/270/320 million [1] - The earnings per share (EPS) estimates for 2025-2027 have been lowered from 0.17/0.20/0.24 to 0.13/0.15/0.18, with a current P/E ratio of 14/12/10 times based on the closing price of HKD 1.96 on February 9, 2026 [1] Group 2 - The domestic milk powder market continues to face challenges, with a decline in the birth rate impacting growth; however, the overseas milk powder market is showing significant growth, particularly in the Middle East, North America, and the CIS regions [2] - In the first half of 2025, Ausnutria's milk powder business experienced a temporary reduction in shipment volumes due to system upgrades and inventory adjustments, leading to a forecasted decline in domestic sheep and cow milk powder business for the year [2] - The company remains optimistic about future growth, planning to expand its presence in the Middle East and continue developing offline channels like Walmart in the U.S. to create a diversified growth engine [2] Group 3 - The infant formula segment has seen success, with Haipinokai being recognized as the top-selling nutritional milk powder for three consecutive years, while Ausnutria's sheep milk powder brand, Jia Bei Ai Te, has gained recognition for its innovative marketing strategies [3] - The approval of a new strain of probiotics for infants by the National Health Commission marks a significant milestone for Jinqi Biotechnology, enhancing its reputation and technological capabilities in the infant nutrition sector [3] - The company aims to solidify its market position and expand its growth trajectory by focusing on consumer needs and leveraging research and innovation to achieve its vision of becoming the most trusted formula milk and nutrition health company globally [3]